At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
Inotuzumab Ozogamicin (CMC-544)drug
Likely dose
Inotuzumab Ozogamicin (CMC-544) 1.8 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study Of Inotuzumab Ozogamicin (Cmc-544) In Subjects With Indolent Non-hodgkin's Lymphoma (Nhl) That Is Refractory To Or Has Relapsed After Rituximab And Chemotherapy Or Radioimmunotherapy
In Brief
A Phase 2 clinical trial evaluating Inotuzumab Ozogamicin (CMC-544) for Lymphoma. Completed, enrolled 81 participants across 42 sites in 9 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin (CMC-544) in subjects with indolent Non-Hodgkins lymphoma (NHL) that is refractory or has relapsed after multiple therapies including rituximab or radioimmunotherapy. The investigational drug will be given to subjects with indolent NHL by intravenous infusion at a dose of 1.8 mg/m2, every 4 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesBelgium, Germany, Hong Kong, Hungary, Japan, Netherlands, Singapore, South Korea, United States
CollaboratorsUCB Pharma
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2009
Enrollment StartJul 2009
Primary CompletionJan 2012
Study CompletionJun 2013
TodayJul 2026
First PostedMar 25, 2009
Enrollment StartJul 30, 2009
Primary CompletionJan 10, 2012
Study CompletionJun 27, 2013
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 17.3 years ago
Interventions
Inotuzumab Ozogamicin (CMC-544)drug
Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles